XML 81 R71.htm IDEA: XBRL DOCUMENT v3.23.1
Collaboration, Licensing and Other Arrangements - Additional Information (Detail) - USD ($)
1 Months Ended 3 Months Ended 12 Months Ended
Dec. 31, 2022
May 31, 2018
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2022
Feb. 28, 2023
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Deferred revenue - current $ 1,733,000   $ 2,316,000   $ 1,733,000  
Deferred revenue - non-current 37,684,000   45,659,000   37,684,000  
Total revenue from UT     40,626,000 $ 11,992,000    
Collaborations and services            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Total revenue from UT     11,386,000 2,166,000    
AFREZZA product sales            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Total revenue from UT     17,562,000 9,826,000    
United Therapeutics Corporation            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Total revenue from UT     23,027,000 2,042,000    
United Therapeutics Corporation | Manufacturing Services            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Funding for development of alternative manufacturing processes 2,300,000          
United Therapeutics Corporation | Commercialization and Continuous Improvement Activities            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Funding for capital improvements 39,500,000          
Thirona Bio, Inc.            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Minimum amount to expended           $ 1,100,000
Collaboration and License Agreement | United Therapeutics Corporation            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Total anticipated cash flows [1] 722,300,000       722,300,000  
Deferred revenue 37,900,000   46,500,000   37,900,000  
Deferred revenue - current 1,600,000   2,200,000   1,600,000  
Deferred revenue - non-current 36,300,000   44,300,000   36,300,000  
Collaboration and License Agreement | United Therapeutics Corporation | Manufacturing Services            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Total anticipated cash flows 722,300,000       722,300,000  
Allocated transaction price 220,800,000          
Collaboration and License Agreement | United Therapeutics Corporation | Manufacturing Services | Transaction Price For The Contractual Obligations            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Total anticipated cash flows 120,000,000.0       120,000,000.0  
Collaboration and License Agreement | United Therapeutics Corporation | Next-Gen R&D Services | Transaction Price For The Performance Obligations            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Total anticipated cash flows $ 602,300,000       602,300,000  
Commercial Supply Agreement | United Therapeutics Corporation            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Total revenue from UT     11,164,000 694,000    
Supply and Distribution Agreement | AFREZZA product sales | Biomm            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Total revenue from UT     0   $ 0  
License and Distribution Agreement | Cipla Ltd            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Deferred revenue     1,500,000      
Deferred revenue - current     200,000      
Deferred revenue - non-current     1,300,000      
Marketing and distribution agreement date   2018-05        
License and Distribution Agreement | Collaborations and services | Cipla Ltd            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Total revenue from UT     $ 37,000 $ 37,000    
[1] The total anticipated cash flow includes a transaction price of $120.0 million for the contractual obligations under the CSA for the Manufacturing Services and the Next-Gen R&D Services performance obligations and $602.3 million for future supply of Tyvaso DPI over the remaining term of the CSA.